ProMIS Neurosciences Shows First Human Evidence of Alzheimer’s Drug Targeting Toxic Oligomers — ProMIS Neurosciences Inc.

Event summary

ProMIS Neurosciences presented first human evidence of dose-dependent reduction of amyloid-beta oligomers by PMN310 at AAIC 2026.
PMN310 demonstrated a dose-dependent decrease in oligomer levels in cerebrospinal fluid (CSF) following a single dose in healthy volunteers.
The company is on track to present six-month blinded interim data from its Phase 1b trial in the coming weeks.
PMN310 was granted Fast Track Designation by the FDA in July 2025.

The big picture

ProMIS Neurosciences’ data at AAIC 2026 marks a significant step in validating its precision medicine approach for Alzheimer’s disease. The focus on selectively targeting toxic amyloid-beta oligomers aligns with growing industry recognition that soluble oligomers, rather than plaques, may be the primary drivers of neurodegeneration. If successful, PMN310 could offer a safer and more effective alternative to current treatments, potentially reshaping the competitive landscape in Alzheimer’s therapeutics.

What we're watching

Clinical Efficacy: Whether PMN310’s ability to reduce amyloid-beta oligomers translates into meaningful clinical outcomes in Alzheimer’s patients.
Regulatory Pathway: The pace at which the FDA will advance PMN310 through subsequent trial phases given its Fast Track Designation.
Competitive Positioning: How ProMIS Neurosciences differentiates PMN310 from existing Alzheimer’s therapies targeting plaques, particularly in avoiding ARIA side effects.